New
HealthMore in Health→
HER2-Targeted Quadruplet Yields 55% Response in Biliary Tract Cancer
Key Takeaways
- Phase 1b/2 HERBOT trial (KCSG-HB23-05) tested first-line trastuzumab, nivolumab, gemcitabine and cisplatin in HER2-positive advanced biliary tract cancer.
- Objective response rate was 55% (95% CI 38.5–70.7), with one complete response and 21 partial responses among 40 participants.
- Disease control rate reached 95% (95% CI 83.5–99.4) and median duration of response was 12.6 months.
- Median progression-free survival was 10.6 months; median overall survival was not reached with median follow-up of 17.0 months.
DE
DT Editorial Team··via nature.com